Tobramycin
Tobramycin is a potent parenteral **aminoglycoside antibiotic** primarily utilized for its excellent efficacy against severe gram-negative aerobic bacterial infections. **Key Clinical Features:** * **Spectrum of Activity:** Highly effective against aerobic gram-negative bacilli (e.g., *Pseudomonas aeruginosa*, *E. coli*, *Klebsiella*, *Proteus*) and some aerobic gram-positive bacteria (e.g., *Staphylococcus*). It is inactive against anaerobes and fungi. * **Clinical Utility:** Due to its inherent toxicity profile, systemic use is typically reserved for serious, life-threatening infections where other less toxic antimicrobials are ineffective, or when treating known gentamicin-resistant strains. * **Toxicity Profile:** Like all aminoglycosides, it carries significant risks of **nephrotoxicity** and **ototoxicity**. Some laboratory evidence suggests it may be slightly less nephrotoxic than gentamicin, though this remains clinically debated. > **Clinical Pearl:** Aminoglycosides exhibit **concentration-dependent bactericidal activity** and a significant **post-antibiotic effect (PAE)**. This pharmacokinetic/pharmacodynamic profile strongly supports the modern practice of high-dose, extended-interval (once-daily) dosing. This approach maximizes the $C_{max}$/MIC ratio for bacterial killing while providing a drug-free interval that allows renal tubular cells to clear the drug, thereby minimizing nephrotoxicity.
Mechanism: Tobramycin is a **bactericidal** antibiotic that disrupts bacterial protein synthesis. * **Cellular Entry:** The drug enters the bacterial cell via an **oxygen-dependent active transport mechanism**. > **Note:** Because this transport requires oxygen, aminoglycosides are completely ineffective against obligate anaerobic bacteria and have reduced efficacy in anaerobic environments (e.g., abscesses, necrotic tissue). * **Target Binding:** Once inside, tobramycin irreversibly binds to the **30S ribosomal subunit**. * **Mechanism:** Binding โ misreading of mRNA โ incorporation of incorrect amino acids into the growing peptide chain โ production of non-functional or toxic proteins โ bacterial cell death. * **Environmental Factors:** Antimicrobial activity is significantly enhanced in an **alkaline environment** and diminished in acidic, purulent conditions.
Dosing by species
- General susceptible infections ยท 2 mg/kg ยท IV, IM, SC ยท q8h ยท Consider consolidating to once-daily dosing.
- Susceptible UTI ยท 1-2 mg/kg ยท SC ยท q8h
- Sepsis ยท 2-4 mg/kg ยท IV ยท q8h
- Soft tissue, systemic infections ยท 2 mg/kg IV, IM or SC q12h or 4 mg/kg IV, IM, SC q24h ยท IV, IM, SC ยท q12h or q24h ยท <= 5 days
- Persistent bacteremia ยท 2 mg/kg IV, IM, SC q8h or 6 mg/kg IV, IM or SC q24h ยท IV, IM, SC ยท q8h or q24h ยท <= 5 days
- Gram-negative infections ยท 4-6 mg/kg ยท IV/IM/SC ยท q24h ยท Assess according to clinical response ยท Cats may be more sensitive to toxicity. For severe infections (including sepsis), doses as high as 12 mg/kg/day have been advocated, but should be used with caution.
- Susceptible infections ยท 4 mg/kg ยท IV ยท q24h ยท Allows achievement of Cmax/MIC ratio higher than 10 for pathogen strains with a MIC of 1 microgram/mL.
- Susceptible infections ยท 5 mg/kg ยท IM ยท q12h
- Susceptible infections ยท 2.5-5 mg/kg/day ยท Parenteral ยท Daily
Routes of administration
Contraindications
- Known hypersensitivity to aminoglycosides
- Rabbits and hares (causes fatal disruption of GI flora)
- Pre-existing severe renal disease (unless benefits outweigh risks)
- Dehydration
- Corneal ulceration (specifically for ophthalmic preparations)
Adverse effects
- Nephrotoxicity (acute tubular necrosis)
- Ototoxicity (vestibular and auditory damage, potentially irreversible)
- Neuromuscular blockade
- Facial edema
- Pain or inflammation at the injection site
- Peripheral neuropathy
- Hypersensitivity reactions
- Rarely: GI signs, hematologic, and hepatic effects
- Ototoxicity (vestibular and auditory damage)
- Neuromuscular blockade (rare)
Drug interactions
- Beta-lactam antibiotics (penicillins, cephalosporins) ยท Synergistic antibacterial effects in vivo; however, can cause physical inactivation of aminoglycosides if mixed in the same syringe or IV line, or in vivo in patients with severe renal failure. ยท moderate
- Cephalosporins ยท Potential for additive nephrotoxicity (historically documented with older generation cephalosporins like cephalothin).
- Loop Diuretics (furosemide, torsemide) ยท Increased risk of nephrotoxicity and ototoxicity.
- Osmotic Diuretics (mannitol) ยท Increased risk of nephrotoxicity and ototoxicity.
- Other Nephrotoxic Drugs (cisplatin, amphotericin B, polymyxin B, vancomycin) ยท Significantly increased risk of acute kidney injury.
- Neuromuscular Blocking Agents & General Anesthetics ยท Concomitant use can potentiate and prolong neuromuscular blockade, potentially leading to respiratory paralysis.
- Amphotericin B ยท Increased risk of nephrotoxicity ยท major
- Furosemide ยท Increased risk of ototoxicity and nephrotoxicity ยท major
- Heparin ยท In vitro chemical inactivation if mixed ยท minor
- Pancuronium ยท Enhanced non-depolarizing neuromuscular blockade ยท moderate
Monitoring
- Clinical efficacy (resolution of fever, improved clinical signs, negative follow-up cultures)
- Renal toxicity: Baseline and serial urinalysis (monitoring for tubular casts, which are often the first sign of impending toxicity), urine specific gravity, serum creatinine, and BUN
- Gross monitoring for vestibular toxicity (head tilt, nystagmus, ataxia) or auditory toxicity (deafness)
- Therapeutic drug monitoring (peak and trough serum levels) is highly recommended to ensure efficacy and prevent toxicity
- Urinalysis (daily, looking for cellular casts as an early warning)
- Serum creatinine and BUN (baseline and periodically)
- Hydration status and urine output
- Auditory and vestibular function
Overdose
In the event of an inadvertent overdose, rapid intervention is required to prevent permanent renal and otic damage: * **Hemodialysis:** Highly effective in reducing serum levels of the drug, though rarely available in veterinary practice. * **Peritoneal Dialysis:** Can reduce serum levels but is significantly less efficacious than hemodialysis. * **Drug Complexation:** Intravenous administration of carbenicillin or ticarcillin (12-20 grams/day in humans) can complex with tobramycin in the blood, inactivating it. This is reportedly nearly as effective as hemodialysis.
VetSheet drug reference is intended for licensed veterinary professionals as a clinical decision-support aid, not a substitute for professional judgement or the manufacturerโs current label.